Vol. 5 No. 1 (2025)
Reimbursement Reviews

Cabotegravir (Apretude)

decorative image of the issue cover

Published January 16, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cabotegravir (Apretude), 30 mg oral tablets and 200 mg/mL (600 mg/3 mL), extended-release injectable suspension.
  • Indication: For at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.